HBG2 and sickle cell disease: With this research we were able to show that CRISPR-Cas9 disruption of a negative regulatory region in HBG1 and HBG2 promoters of autologous hematopoietic stem cells (HSCs) obtained from participants with sickle cell disease resulted in induction of red-cell fetal hemoglobin and a partial correction of sickle cell disease.